Biolligence

🌟 Year in Review: 2024 🌟 As we approach the end of the year, we at Biolligence are reflecting on what has been an incredible journey filled with milestones, learnings, and growth. This year, we made significant strides in our mission to transform drug discovery and development: 🎯 Key Achievements in 2024 Developed BioTox Platform, bringing human-relevant toxicity predictions to the forefront of drug development. In discussion with leading pharmaceutical companies to generate actionable insights and accelerate safer drug development. Expanded our AI-driven capabilities, integrating GenerativeAI and ExplainableAI to empower precision medicine. Built a talented, diverse team of experts passionate about creating meaningful scientific impact. 🙏 Thank You To our partners, collaborators, mentors, and supporters - thank you for believing in our vision and contributing to our progress. Your encouragement and trust drive us to innovate and push boundaries every day. 🚀 Looking Ahead We’re excited about the opportunities that 2025 holds and are committed to creating a greater impact in science. Together, let’s shape a future of safer, more effective therapies and transformative advancements in healthcare. Wishing everyone a fantastic New Year filled with success, health, and innovation! We’re excited to announce that our AI platform will be launching soon! Join our waiting list today to be among the first to experience an exclusive demo. https://lnkd.in/gC7x28UE Stay tuned for more updates and breakthroughs from Biolligence. 💡

Exciting News! 🚀 We’re thrilled to announce that BioTox, our cutting-edge clinical toxicity prediction tool, is launching soon! 🎉 Join our waiting list: https://lnkd.in/gC7x28UE What is BioTox? BioTox leverages advanced AI to predict clinical toxicity with unparalleled precision, helping researchers and scientists design safer, more effective drugs. By analyzing vast datasets and incorporating human-relevant insights, BioTox empowers precision drug design, reduces late-stage failures, and accelerates the journey from lab to patient. Why Choose BioTox? Accurate Predictions: Anticipate toxicity risks with confidence. Human-Centric Approach: Better align drug safety with real-world patient outcomes. Faster Development: Minimize setbacks and optimize R&D timelines. Be a part of this transformative journey in drug discovery and safety. Join our waiting list today and be among the first to experience the power of BioTox!

🌟 Exciting News from Biolligence! 🌟 We’re proud to announce that Biolligence is now part of the Microsoft for Startups Founders Hub! This is a significant milestone for us as we continue our journey to redefine drug discovery and safety with AI-driven innovation. This program is more than just an opportunity; it’s a platform that provides us with advanced cloud capabilities, access to AI tools, and expert mentorship. With these resources, we’re enhancing our ability to work with complex datasets, perform large-scale simulations, and create impactful insights for scientists and researchers worldwide. At Biolligence, we believe in the power of technology to transform how we approach drug development. This partnership fuels our vision to make science faster, smarter, and more precise. Here’s to pushing boundaries and making a difference in healthcare! 🧬💡 Want to learn more about what we do at Biolligence? Contact us here: https://lnkd.in/gC7x28UE #Biolligence #DrugDiscovery #AI #FoundersHub #Innovation #HealthTech

Data is the key that unlocks the true potential of AI. 🔑🤖 At Biolligence, we don't just collect data — we transform it into high-quality, well-structured information that serves as a solid foundation for AI models. By curating, storing, and analyzing this data, we derive impactful insights that enable better predictions and drive meaningful outcomes. 📊💡 Whether it’s advancing drug discovery or tackling complex challenges in biology, we believe that great AI starts with great data. Let’s build smarter, data-driven solutions for a brighter future! 🚀 We leverage high-quality clinical data to train our deep learning models, enabling us to derive impactful insights for drug safety at a population scale. These insights play a crucial role in designing precision clinical trials. Feel free to contact us for more details at hello@biolligence.com www.biolligence.com #DataIsKey #AI #DataScience #Innovation

Recent developments in the pharmaceutical industry have highlighted several instances where drug candidates were discontinued due to toxicity concerns: 1. Incyte Corporation's MRGPRX2 and MRGPRX4 Programs In November 2024, Incyte Corporation halted the enrollment in its Phase 2 trial of MRGPRX2 (INCB000262) for treating chronic spontaneous urticaria after preclinical studies revealed toxicological concerns. Additionally, the company discontinued the development of MRGPRX4 (INCB000547) for cholestatic pruritus due to insufficient efficacy data. These decisions led to a significant decline in Incyte's stock value. https://lnkd.in/dj78XeWm 2. Tango Therapeutics' TNG348 In May 2024, Tango Therapeutics ceased the development of its experimental cancer therapy, TNG348, following the observation of liver toxicity in patients during early-stage trials. The therapy was being tested both as a monotherapy and in combination with AstraZeneca and Merck's Lynparza. The discontinuation was prompted by serious liver function abnormalities in patients who had been in the study for over eight weeks. https://lnkd.in/dAnndz3H These cases underscore the critical importance of thorough toxicity evaluation in drug development to ensure patient safety and the viability of new therapies. We generate human data before clinical trials and help you identify detail safety profile of your molecules. Do reach out to our team at hello@biolligence.com

In drug safety research, the integration of wet labs and dry labs is crucial. Wet labs conduct hands-on experiments with chemicals and biological samples, providing empirical data on drug interactions and effects. Dry labs utilize computational tools to analyze this data, offering insights through simulations and modeling. This collaboration enhances the accuracy of safety assessments, accelerates drug development, and fosters innovation. By bridging experimental research with computational analysis, we can develop safer, more effective therapeutics.

Great to see such initiatives from the Indian government. R & D activities growing and India is transforming!

🎉 Exciting News! 🎉 We’re thrilled to announce the launch of our official website: www.biolligence.com 🌐🚀 At Biolligence, we’re dedicated to advancing science at the interface of biology and deep learning. Our mission is to harness the power of data and AI to create impactful solutions for the life sciences & pharma industry. Explore our journey, innovative offerings, and how we aim to redefine the boundaries of biology and technology. Visit us, connect with us, and join us in shaping the future of bioscience innovation. 💡🔬 #Biolligence #Innovation #AIinBiology #LifeSciences #DrugSafety